Cycloalkyl-substituted aryl chloroethylureas inhibiting cell cycle progression in G0/G1 phase and thioredoxin-1 nuclear translocation

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 12, 2008, Pages 3526-3531

  Fortin, Jessica S ^a,b   Côté, Marie France ^a   Lacroix, Jacques ^a   Patenaude, Alexandre ^a,b   Petitclerc, Éric ^a,b   C Gaudreault, René ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Alkylating agents; Anticancer drugs; Phenyl chloroethylurea; Thioredoxin 1

Indexed keywords

1 (2 CHLOROETHYL) 3 (4 CYCLOHEXYLPHENYL)UREA; CHLOROETHYLUREA DERIVATIVE; CISPLATIN; CYTOPLASM PROTEIN; PHENYL GROUP; THIOREDOXIN 1; UREA DERIVATIVE;

ALKYLATION; ARTICLE; BREAST CARCINOMA; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL DIVISION; CELL FRACTIONATION; CELL NUCLEUS; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; DRUG SYNTHESIS; GENE TRANSLOCATION; HUMAN; HUMAN CELL; MELANOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; WESTERN BLOTTING;

EID: 44649089299     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.05.028     Document Type: Article

References (38)

1. C.-Gaudreault R., Lacroix J., Pagé M., and Joly L.P. J. Pharm. Sci. 77 (1988) 185
2. C.-Gaudreault R., Alaoui-Jamali M.A., Batist G., Béchard P., Lacroix J., and Poyet P. Cancer Chemother. Pharmacol. 33 (1994) 489
3. Legault J., Gaulin J.-F., Mounetou E., Ritchot N., Lacroix J., Poyet P., and C.-Gaudreault R. Cancer Res. 60 (2000) 985
4. Bouchon B., Chambon C., Mounetou E., Papon J., Miot-Noirault E., C.-Gaudreault R., Madelmont J.-C., and Degoul F. Mol. Pharmacol. 68 (2005) 1415
5. Petitclerc E., Deschesnes R.G., Côté M.-F., Marquis C., Janvier R., Lacroix J., Miot-Noirault E., Legault J., Mounetou E., Madelmont J.-C., and C.-Gaudreault R. Cancer Res. 64 (2004) 4654
6. Béchard P., Lacroix J., Poyet P., and C.-Gaudreault R. Eur. J. Med. Chem. 29 (1994) 963
7. Mounetou E., Legault J., Lacroix J., and C.-Gaudreault R. J. Med. Chem. 44 (2001) 694
8. Mounetou E., Legault J., Lacroix J., and C.-Gaudreault R. J. Med. Chem. 46 (2003) 5055
9. Moreau E., Fortin S., Desjardins M., Rousseau J.L.C., Petitclerc E., and C.-Gaudreault R. Bioorg. Med. Chem. 13 (2005) 6703
10. Fortin J.S., Lacroix J., Desjardins M., Patenaude A., Petitclerc E., and C.-Gaudreault R. Bioorg. Med. Chem. 15 (2007) 4456
11. Borel M., Degoul F., Communal Y., Mounetou E., Bouchon B., C.-Gaudreault R., Madelmont J.-C., and Miot-Noirault E. Br. J. Cancer 96 (2007) 1684
12. Miot-Noirault E., Legault J., Cachin F., Mounetou E., Degoul F., C.-Gaudreault R., Moins N., and Madelmont J.-C. Invest. New Drugs 4 (2004) 369
13. Patenaude A., Deschesnes R.G., Rousseau J.L., Petitclerc E., Lacroix J., Cote M.F., and C.-Gaudreault R. Cancer Res. 67 (2007) 2306
14. Bouchon B., Papon J., Communal Y., Madelmont J.C., and Degoul F. Br. J. Pharmacol. 152 (2007) 449
15. Nishinaka Y., Nakamura H., Masutani H., and Yodoi J. Arch. Immunol. Ther. Exp. (Warz) 49 (2001) 285
16. Powis G., Mustacich D., and Coon A. Free Radic. Biol. Med. 29 (2000) 312
17. Baker A., Payne C., Briehl M.M., and Powis G. Cancer Res. 57 (1997) 5162
18. Watson W.H., Chen Y., and Jones D.P. Biofactors 17 (2003) 307
19. Yokomizo A., Ono M., Nanri H., Makino Y., Ohga T., Wada M., Okamoto T., Yodo i.J., Kuwano M., and Kohno K. Cancer Res. 55 (1995) 4293
20. Pennington J.D., Wang T.J.C., Nguyen P., Sun L., Bisht K., Smart D., and Gius D. Drug Resist. Updat. 8 (2005) 322
21. Chen X.P., Liu S., Tang W.X., and Chen Z.W. Biochem. Biophys. Res. Commun. 361 (2007) 362
22. Rosell R., Cecere F., Santarpia M., Reguart N., and Taron M. Curr. Opin. Pharmacol. 6 (2006) 323
23. Arnold N.B., Ketterer K., Kleeff J., Friess H., Buchler M.W., and Korc M. Cancer Res. 64 (2004) 3599
24. Bracht K., Liebeke M., Ritter C.A., Grunert R., and Bednarski P.J. Anticancer Drugs 18 (2007) 389
25. Burke-G. A., Callister M.E.J., and Nakamura H. Trends Pharmacol. Sci. 26 (2005) 398
26. Zhao R., and Holmgren A. J. Biol. Chem. 277 (2002) 39456
27. Baker A.F., Dragovich T., Tate W.R., Ramanathan R.K., Roe D., Hsu C.-H., Kirkpatrick D.L., and Powis G. J. Lab. Clin. Med. 147 (2006) 83
28. Powis G., and Kirkpatrick D.L. Curr. Opin. Pharmacol. 7 (2007) 392
29. Arner E.S., and Holmgren A. Semin. Cancer Biol. 16 (2006) 420
30. Available from: http://www.prolx.com.
31. Carrigan N.C., Barlett D.B., Esslinger S., Cybulski A.K., Tongcharoensirikul P., Bridge J.R., and Thompson M.C. J. Med. Chem. 45 (2002) 2260
32. Kirkpatrick D.L., Jimale M.L., King K.M., and Chen T. Eur. J. Med. Chem. 27 (1992) 33
33. Shoemaker R.H. Nat. Rev. Cancer 6 (2006) 813
34. Ueno M., Masutani H., Arai R.J., Yamauchi A., Hirota K., Sakai T., Inamoto T., Yamaoka Y., Yodoi J., and Nikaido T. J. Biol. Chem. 274 (1999) 35809
35. Tashiro E., Tsuchiya A., and Imoto M. Cancer Sci. 98 (2007) 629
36. Donaldson K.L., Goolsby G.L., and Wahl A.F. Int. J. Cancer 57 (1994) 847
37. Wang X., Cheung H.W., Chun A.C., Jin D.Y., and Wong Y.C. Front. Biosci. 13 (2008) 2103
38. Rixe O., and Fojo T. Clin. Cancer Res. 13 (2007) 7280